Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones

Antimicrob Agents Chemother. 1995 Feb;39(2):489-95. doi: 10.1128/AAC.39.2.489.

Abstract

Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone-containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 micrograms/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coli gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Bacterial Outer Membrane Proteins / analysis
  • DNA Gyrase
  • DNA Topoisomerases, Type II / genetics
  • Drug Resistance, Microbial
  • Drug Resistance, Multiple
  • Escherichia coli / enzymology
  • Microbial Sensitivity Tests
  • Pefloxacin / pharmacokinetics
  • Porins / analysis
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / growth & development

Substances

  • Anti-Infective Agents
  • Bacterial Outer Membrane Proteins
  • Porins
  • Pefloxacin
  • DNA Gyrase
  • DNA Topoisomerases, Type II